Kornimate/medical-research-clean huggingface dataset:
apoptotic cell (ac) uptake by human alveolar macrophages (am)

Conditions: Chronic Obstructive Pulmonary Disease

Summary: the purpose of this study is to compare the ability of two types of white blood cells to eat dead host cells, and how this process affects their ability to protect the body from infection. the two cell types are monocytes, a cell in the bloodstream, and alveolar macrophages, a cell in the lung that is ultimately derived from monocytes

volunteers, who may be veterans or non-veterans, will be screened by a series of questionnaires, chest x-ray, spirometry, ekg, blood work, and a complete history and physician examination by a study physician. those who qualify for the study and agree via informed consent, will undergo a fiberoptic bronchoscopy on a separate day for the initial visit. bronchoscopy is a procedure in which a flexible video instrument is passed via the nose or mouth, through the vocal cords and into the lungs. during the procedure, portions of the lungs will be washed ("lavaged") with a salt water solution, to collect the alveolar macrophages. this procedure involves conscious sedation, so that a driver is required on the day of the bronchoscopy. the entire procedure, including placement of an intravenous line to administer medications, local anesthetics, the bronchoscopy itself, and the recovery period, takes about 2.5-3 hours. the cells collected by bronchoscopy will be studied in the research laboratory, and used entirely in that procedure.

Eligibility criteria:
inclusion criteria: * veteran or non-veteran * able to give informed consent exclusion criteria: * unstable heart disease * other systemic disease and unlikely to survive at least 2 years * mental incompetence * prednisone \>20 mg/day * participation in another interventional protocol within last 6 weeks * asthma * cystic fibrosis * clinically significant bronchiectasis * lung cancer or any cancer not in remission for at least 5 years * other inflammatory or fibrotic lung disease * use of antibiotics for a lung infection within the past 4 weeks * autoimmune disease, i.e., rheumatoid arthritis, systemic lupus erythematosus, autoimmune hepatitis, crohn's disease or other

Keywords: macrophages, alveolar monocytes receptor protein-tyrosine kinases humans phagocytosis lung in vitro
a study of ly2963016 compared to lantus® in adult chinese participants with type 2 diabetes mellitus

Conditions: Type 2 Diabetes

Summary: the purpose of this study is to compare long-acting basal insulin analog ly2963016 to lantus® in insulin naïve adult chinese participants with type 2 diabetes mellitus (t2dm) on 2 or more oral antihyperglycemic medications (oams). participants will continue their oams throughout the study.


Eligibility criteria:
inclusion criteria: * have t2dm based on the disease diagnostic criteria world health organization (who) classification. * have been receiving 2 or more oams at stable doses for the 12 weeks prior to screening. * have a hba1c ≥7.0% and ≤11.0%. * body mass index (bmi) ≤35 kilograms per meter squared. exclusion criteria: * have used insulin therapy (outside of pregnancy) anytime in the past 1 year, except for short-term treatment of acute conditions, and up to a maximum of 4 continuous weeks. * have used any glucagon like peptide (glp-1) receptor agonists within the previous 90 days. * are currently taking traditional medicine (herbal medicine or patent medicine) with known/specified content of anti-hyperglycemic effects within 3 months before screening. * have had more than one episode of severe hypoglycemia within 6 months prior to entry into the study. * have had ≥2 emergency room visits or hospitalizations due to poor glucose control. * have known hypersensitivity or allergy to lantus® or its excipients. * are receiving chronic systemic glucocorticoid therapy at pharmacological doses or have received such therapy within 4 weeks immediately preceding screening. * have obvious signs or symptoms, or laboratory evidence, of liver disease. * have one of the following concomitant diseases: significant cardiac or gastrointestinal disease. * have a history of renal transplantation, are currently receiving renal dialysis or have a serum creatinine greater than 2.0 milligrams per deciliter. * have had a blood transfusion or severe blood loss within 3 months prior to screening or have known hemoglobinopathy, hemolytic anemia, or sickle cell anemia. * participants with active cancer or personal history of cancer within the previous 5 years. * are pregnant or intend to become pregnant during the course of the study. * are women who are breastfeeding.

Keywords: insulin glargine
botulinum toxin therapy in hidradenitis suppurativa

Conditions: Hidradenitis Suppurativa; Hyperhidrosis

Summary: this study will build on data from mice and humans implicating trpv1 nociceptors in the pathogenesis of the type-17 chronic inflammatory skin disease hidradenitis suppurativa (hs). in this study, the investigators will test the hypothesis that inhibiting neuropeptide activity with botulinum toxin reduces pathogenic inflammation.

botulinum toxin prevents vesicle fusion at nerve terminals thereby inhibiting neuropeptide release. the investigators will collect punch biopsies of lesional skin from hs patients before, and 1-2 months after botulinum toxin treatment (50u per axilla in 10 injections of 0.1ml) then perform flow cytometric, transcriptomic, and microscopic analysis of skin to determine if nonselective inhibition of neuropeptide release diminishes il-17 driven skin inflammation.

Eligibility criteria:
inclusion: * adults between ages 18 and 75 years with established diagnosis of hidradenitis suppurativa (hs) * hs skin lesions of duration at least 1 year, hs skin lesions in at least two different body areas exclusion: * age \ 75 years * pregnant or breastfeeding * neuromuscular disorder (ex. als, myasthenia gravis, lambert-eaton syndrome, myopathy) * medical co-morbidity that is a relative contraindication to skin biopsy procedure (ex. end stage congestive heart failure or coagulopathy) * active bacterial, fungal, or viral infection in the treatment area * known hypersensitivity to botulinum toxin a preparations or any of their components (human albumin, saline, lactose, sodium succinate) * prisoners * adults unable to consent for themselves.
duration of protective effect from inhaled ipratropium bromide on methacholine airway hyperresponsiveness

Conditions: Asthma

Summary: certain lung disease medications can influence diagnostic tests and research investigations. this study will investigate how long ipratropium bromide must be withheld before a methacholine challenge test can be conducted. this information will be useful for validating current guidelines.


Eligibility criteria:
inclusion criteria: * diagnosis of asthma; stable and controlled * fev1 greater than or equal to 65% predicted exclusion criteria: * concomitant lung disease other than asthma

Keywords: methacholine bronchoprovocation antimuscarinic
biomarker guided treatment in gynaecological cancer

Conditions: Endometrial Cancer

Summary: momatec2 aims to test, in clinically oriented studies, the applicability of already identified and promising molecular biomarkers, to promote individualisation of treatment for patients with endometrial cancer. predominantly, but not exclusively, such biomarkers have shown to be interesting in retrospective analysis of our large prospectively collected momatec1 series. part 1: performance of a phase 4 implementation trial for optimised stratification of surgical treatment, specifically the performance of (para-aortic and pelvic) lymphadenectomy guided by validated biomarkers. part 2: performance of a phase 2b clinical biomarker study to evaluate the predictive potential of the biomarker stathmin for taxane treatment response in endometrial and ovarian cancer. in this study stathmin will be used as integrated biomarker.


Eligibility criteria:
inclusion criteria part 1: all patients referred to a participating research centre with suspicion of or confirmed endometrial cancer. exclusion criteria part 1: 1. patients who do not have endometrial cancer 2. patients who will or cannot give informed consent (including language barriers) 3. patients \<18 years of age 4. patients who will not get surgical treatment for their endometrial cancer inclusion criteria part 2: 1. patients with endometrial or epithelial ovarian cancer who following routine clinical guidelines are offered weekly taxane (paclitaxel) treatment. this will often be a third or fourth line treatment, i.e. patients with advanced disease. 2. technical possibility to obtain a new tissue biopsy to determine stathmin level in the tumour recurrence. exclusion criteria part 2: 1. patients not suffering from endometrial or epithelial ovarian cancer 2. patients \<18 years of age 3. patients who do not agree to the proposed treatment or will receive (part of) the treatment in a non-participating centre 4. patients who cannot or do not want to give informed consent (including language barriers)
investigation of hand functions and related parameters in people with multiple sclerosis

Conditions: Multiple Sclerosis

Summary: the upper extremity in people with multiple sclerosis (pwms) has become a more popular research topic in recent years, with the increase in studies reporting widespread involvement. the aim of our study was to evaluate the upper extremity from multiple perspectives in early stage pwms, to identify problems by comparing them with healthy individuals, and to examine the relationship of problems with activity and participation.


Eligibility criteria:
inclusion criteria: * ms diagnosis according to mcdonald criteria * relapsing remitting ms clinical course type * 18-65 age range * being able to understand and read turkish exclusion criteria: * having an ms attack in the last 3 months * to have done regular exercise for the upper extremity in the 6 months before starting the study * having different neurological, orthopedic or cardiac problems other than ms * being addicted to alcohol or drugs * getting a score below 24 on the mini mental test scale * having a spasticity of 3 or more according to the modified ashworth scale

Keywords: multiple sclerosis upper limb function activity participation
hcc staging modified by tumor micronecrosis

Conditions: Hepatocellular Carcinoma

Summary: tumor micronecrosis is a pathological feature that reflects malignant biological behavior in hepatocellular carcinoma (hcc). this study aimed to evaluate the prognostic significance of tumor micronecrosis based on the current bclc and tnm staging systems, and futher improve the performance of the staging models by establishing modified new staging models including tumor micronecrosis.


Eligibility criteria:
inclusion criteria: * primary and histologically confirmed hccs * patients who underwent curative liver resection exclusion criteria: * simultaneous presence of other tumors * patients who had received preoperative antitumor therapies * no available surgical specimens for evaluating micronecrosis status * gross tumor necrosis and nscore = 3

Keywords: hepatocellular carcinoma tumor micronecrosis bclc tnm disease staging
investigation of 2 different oral formulations of estradiol and norethisterone in healthy women

Conditions: Menopause; Healthy

Summary: this trial is conducted in europe. the aim of this trial is to investigate whether a reformulated estradiol/norethisterone acetate (neta) formulation is bioequivalent to that of kliogest® (estradiol/norethisterone acetate (neta) in healthy women.


Eligibility criteria:
inclusion criteria: * postmenopausal defined as at least 12 months spontaneous amenorrhoea, with serum fsh (follicle stimulating hormone) levels at least 40 iu/l and estradiol maximum 25 pg/ml. if the date of spontaneous amenorrhoea can not be identified because of previous hormone replacement therapy, serum fsh at least 40 iu/l and estradiol maximum 25 pg/ml * non-smoking * body mass index (bmi) maximum 35.0 kg/m\^2 * able to understand, read and speak german fluently * good state of health evidenced by medical history, physical examination including gynecological examination, and results from laboratory examination * willing to abstain from intake of caffeine containing food and beverages within 48 hours before drug administration exclusion criteria: * known or suspected allergy to trial products or related products * previous use of oral, transdermal, nasal spray, vaginal preparations and implants within 8 weeks prior to the planned first drug administration * known, suspected or history of breast cancer * known or suspected estrogen dependent neoplasia e.g. endometrial cancer * abnormal genital bleeding of unknown aetiology * known insulin dependent as well as non-insulin dependent diabetes mellitus * positive test for hiv (human immunodeficiency virus) and/or hepatitis b and c * systolic blood pressure (bp) above or equal to 160 mm hg and/or diastolic bp above or equal to 100 mm hg, currently treated or untreated
validation study of a new cytokine-based dynamic stratification based on flt3 ligand plasma concentration kinetic profile and il-6 concentration during induction of acute myeloid leukemia

Conditions: Acute Myeloid Leukemia

Summary: the investigators have recently demonstrated the strong impact in terms of survivals of fms-like tyrosine kinase 3 ligand (fl) levels evaluated during intensive induction in acute myeloid leukemia (aml) patients. indeed, three fl kinetic profiles were delineated: i) sustained increase of fl concentrations between day (d) 1 and d22 (fli group, n=26, good-risk), ii) increase from d1 to d15, then decrease at d22 (fld group, n=22, intermediate-risk) and iii) stagnation of low levels (\<1000 pg/ml, fll group, n=14, high-risk). however, with longer follow-up, the investigators have observed that fli and fld shared similar outcomes while fll sub-group kept a very bad prognostic. because serum samples from this previous study (called the flam/flal study) had been frozen-stored, the investigators were able to conduct an ancillary study assessing the potential impact of the kinetics of 6 other cytokines: tnfalpha, stem-cell factor, il-1beta, il-6, il-10 and granulocyte-monocyte colony-stimulating factor (gm-csf).. only il-6 level at d22 (\ 15.5 pg/ml) was associated with outcome allowing to distinguish between higher and lower survivals within the combined fli/fld sub-group. a new prognostic risk-stratification can thus be proposed as follows: fli/fld with il-6 \ 15.5 pg/ml (intermediate) and fll (high-risk). the aim of this new flamval study is to validate prospectively in a larger and independent cohort this prognostic risk-stratification i.e. that kinetic profile of flt3l plasma level from d1 to d22 and il6 plasma level at day 22 during induction of aml patients are predictive of overall and disease free survivals. for that purpose, 201 newly diagnosed aml patients treated intensively in the 25 centres of the french innovative leukemia organisation (filo) will be included in the flamval study.


Eligibility criteria:
inclusion criteria: * age \>= 18 years old * confirmed diagnosis of aml according to world health organization (who) 2016 classification (arber et al., 2016) * non previously treated aml (first-line therapy) * patients eligible to standard 3+7 induction chemotherapy with a minimum of 3 days of daunorubicin at 45mg/m2/day or a minimum of 5 days of idarubicin at 8mg/m2/day and a minimum of 7 days of cytarabin at 100mg/m2/day * patients receiving any "third drug" combined to the "3+7" scheme, i.e. lomustine, corticotherapy, elthrombopag, gemtuzumab-ozogamycin, any flt3 inhibitors... are eligible * patients receiving cpx-351 (vyxeos ®) are eligible * patients requiring leukapheresis are eligible * signed informed consent exclusion criteria: * patients diagnosed with acute promyelocytic leukemia (aml-3) * adults under guardianship, subjects under protection.
a clinical study comparing basic performance and hemocompatibility of 3 different dialyzers in hemodialysis patients

Conditions: End Stage Renal Disease (ESRD)

Summary: the aim of the study is to confirm the safety and clinical effectiveness of nipro elisio-15h and to compare its performance characteristics and hemocompatibility with those of the commercially available dialyzers in u.s.a., gambro polyflux revaclear and fresenius f160nre. 10 stable patients will be dialyzed 3 times/week with each dialyzer over 3 weeks. blood samples for several parameters will be collected during hemodialysis to assess the performance and hemocompatibility of the dialyzers under study. data thus collected will be analyzed for comparison by standard statistical analysis.

current patients receiving dialysis treatment for end stage renal disease and who meet the inclusion/exclusion criteria will be entered into the study. these patients will continue on their standard dialysis regimen as stated in the clinics standard operating procedures. each patient will be studied for three weeks with each week starting with a dialyzer of a different manufacture but of comparable characteristics. solute clearances and removal will be determined at each of the three dialysis sessions during the week. during session 2 of each week additional specimens will be taken to analyze for hemocompatibility. at the end of the study all clearances and the hemocompatibility markers for each dialyzer will be compared to one another as well as to the manufactures stated characteristics. blood for the clearance and removal calculations will be taken at time 0, 60 minutes and 240 minutes. blood for the hemocompatibility determinations will be taken at time 0, 15, 30, 60 and 240 minutes. flow rates, anticoagulant therapy, erythropoietin therapy, venous and arterial pressures will also be recorded.

Eligibility criteria:
inclusion criteria: * esrd patients 18 years or older * stable on hemodialysis for more than 3 months * stable hemoglobin between 11-12 g/dl * stable arteriovenous (av) fistula vascular access * stable anticoagulation and esa regimen * no active infection * able to sign informed consent and able to participate in the study * medically stable exclusion criteria: * participation in another study which may interfere with the planned study * active infection * medical conditions which may interfere with the study (cardiac, liver disease, hepatitis) * allergy to dialyzer membrane materials e.g. polysulfone * patients which cannot tolerate heparin * female who are pregnant or planning to be pregnant * problem with or allergy to anticoagulation
trial of sodium valproate in amyotrophic lateral sclerosis

Conditions: Amyotrophic Lateral Sclerosis

Summary: the purpose of this study is to determine whether the use of sodium valproate is effective in slowing the disease progression in amyotrophic lateral sclerosis.

amyotrophic lateral sclerosis (als) is a devastating disease characterized by progressive degeneration of motor neurons leading to muscle weakness. the pathogenesis of als is unknown, but there is convincing evidence that several molecular mechanisms play a role. previous studies investigated the role of the survival motor neuron (smn) gene in als. recent data suggest that smn genotypes producing less smn protein increase susceptibility and severity of als. this leads to the hypothesis that the clinical expression of als is influenced by the total smn protein level in affected patients. in a population of als patients in the netherlands we found that smn genotypes producing less smn protein appear to increase susceptibility and severity of als. it was shown that the hdac inhibitor sodium valproate (svp) increases levels of smn protein in vitro. from these results and from data suggesting neuroprotective properties of svp, it is hypothesised that svp could extend survival of patients with als. in addition, sodium valproate significantly prolonged the disease duration in the animal model for als, the sod1 transgenic mouse. given that svp is a fda-approved compound with well-known pharmacokinetic and toxicity profiles, it is an attractive candidate for a clinical trial in als patients.

Eligibility criteria:
inclusion criteria: * definite, probable, or probable-laboratory supported als according to the revised el escorial world federation of neurology criteria. * intake of riluzole 50 mg twice a day (bid) * a disease duration at inclusion of more than 6 months and less than 36 months \[inclusive\] (disease onset is defined as the date of first symptoms excluding muscle cramps and fasciculations) * vital capacity (vc%) ≥ 70% of normal value (slow expiration, best of a minimum of three and a maximum of five measurements, with a respiratory function validly assessable and a spontaneous, non-assisted ventilation) * ages 18 - 85 years (inclusive) * capable of thoroughly understanding the trial information given; has signed the informed consent. exclusion criteria: * tracheostomy, tracheostomal ventilation of any type, non-invasive ventilation more than 16 hours/ day, or supplemental oxygen during the last three months prior to inclusion. * any medical condition or intoxication known to have an association with motor neuron dysfunction, which might confound or obscure the diagnosis of als. * presence of any concomitant life-threatening disease or any disease or impairment likely to interfere with functional assessment. * confirmed hepatic insufficiency or abnormal liver function (asat, alat greater than twice the upper limit of normal range).

Keywords: als sodium valproate randomised trial amyotrophic lateral sclerosis (als)
stereotactic radiotherapy for sinonasal malignancy

Conditions: Head and Neck Neoplasms

Summary: sinonasal tumors are a rare type of head and neck tumor, accounting for approximately 3% of head and neck cancers. treatment primarily involves surgical intervention, with radiation therapy as an adjunct. due to the tumor\&#39;s anatomical location near critical structures such as the eyes, optic nerves, optic chiasm, brainstem, and oral cavity, if the tumor cannot be completely resected, postoperative radiation therapy is often necessary. given the complexity of the tumor\&#39;s anatomical position, subsequent radiation therapy planning becomes more challenging, as it must balance tumor control and organ preservation. this study retrospectively analyzes patients with sinonasal tumors who received stereotactic radiosurgery (cyberknife) at our hospital, comparing the dosimetric advantages, treatment efficacy, survival analysis, and side effects with those of volumetric modulated arc therapy (vmat).


Eligibility criteria:
inclusion criteria: * the pathological tissue report from the endoscopic surgery at this hospital confirmed a diagnosis of malignant sinus tumor. * received radical stereotactic radiotherapy at this hospital. * pre-treatment baseline imaging (ct or mri) was performed. * received radical radiotherapy at this hospital and has been under long-term follow-up with complete medical records at this hospital. exclusion criteria: * local lymphatic metastasis and distant metastasis have been excluded by imaging examinations (cn \&gt;=1, m =1). * not treated with radical radiotherapy at this hospital and has been under long-term follow-up at this hospital with incomplete medical records.

Keywords: sinonasal malignancy sbrt cyberknife